How Does Atrial Natriuretic Peptide Work? Mechanism of Action, Per the Research

The short version of the mechanism

Atrial natriuretic peptide (ANP) is a peptide hormone secreted mainly by atrial cardiomyocytes in response to wall stretch. Reviews of natriuretic peptide biology described the family as signalling through membrane-bound guanylyl cyclase receptors that generate cyclic guanosine monophosphate (cGMP) as the second messenger, with downstream effects on sodium handling, vascular tone and cardiac remodelling (PMID 31398927). A 2020 endocrine review similarly framed the natriuretic peptides as cardiac hormones whose signalling reaches the kidney, vasculature, adipose tissue and other organs, and which are measured clinically as markers of cardiac wall stress (PMID 32537542).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or cardiovascular disease. It describes what researchers reported about mechanism, not what anyone should do.

Where ANP comes from

ANP is stored in atrial granules as a prohormone and released when the atria are stretched, the classic stimulus being volume loading. Reviews of cardiovascular pharmacology described the heart in this context as an endocrine organ whose peptide output feeds back on circulating volume and vascular resistance (PMID 16492551). The prohormone is cleaved, and the literature has given attention to more than one fragment: a 2021 review focused specifically on ANP(31-67), a mid-region prohormone fragment, and examined its signalling and candidate roles in cardiovascular disease (PMID 34305645). That review illustrates a recurring theme, the pro-ANP molecule yields several circulating products, and not all of them act through the same pathway as the classic 28-amino-acid peptide.

Secretion is not purely mechanical. Researchers reviewing oxytocin and cardiovascular protection discussed the heart's own endocrine signalling as part of the cardioprotective picture, placing natriuretic peptide release within a wider neuro-cardiac control system (PMID 32982875).

Receptor targets: NPR-A, NPR-B and NPR-C

Three natriuretic peptide receptors are described in the pharmacology literature.

• NPR-A (GC-A, NPR1), the principal signalling receptor for ANP. Reviews describe it as a single-pass membrane protein with an intracellular guanylyl cyclase domain that converts GTP to cGMP when the peptide binds the extracellular domain (PMID 31398927).
• NPR-B (GC-B, NPR2), structurally similar but preferentially activated by C-type natriuretic peptide rather than ANP, and reviewed as part of the same guanylyl cyclase receptor family (PMID 32537542).
• NPR-C (clearance receptor), lacks the cyclase domain and is described primarily as a clearance and buffering receptor, with some reports of G-protein-linked signalling (PMID 31398927).

Receptor density varies by tissue, which is one reason the same circulating peptide produces different local effects in kidney, blood vessel wall and heart, as reviewed in the natriuretic peptide pleiotropy literature (PMID 31398927).

The core second messenger: cGMP and protein kinase G

Once NPR-A is occupied, the intracellular catalytic domain generates cGMP. Reviews of natriuretic peptide signalling describe cGMP as the convergence point for the hormone's actions, acting through cGMP-dependent protein kinase (PKG), cGMP-gated ion channels and cGMP-regulated phosphodiesterases (PMID 31398927). A 2002 review of cGMP signalling in podocytes examined this pathway at the level of a single specialised renal cell type, describing how natriuretic peptide and nitric oxide inputs converge on cGMP within the glomerular filtration barrier (PMID 12012390), cell-level work of that kind sits upstream of whole-organ conclusions and should be read as such.

Signal termination matters as much as signal generation. Guanylyl cyclase receptors are regulated in part by their phosphorylation state, and reviews of serine/threonine phosphatases, including a 2008 review of protein phosphatase 5, describe how phosphatase activity shapes the duration and amplitude of kinase-dependent signalling in general (PMID 17951098). This is background cell biology rather than ANP-specific proof.

Downstream physiology, as described in reviews

Kidney: natriuresis and diuresis

The name of the peptide follows its best-characterised action. Reviews of natriuretic peptide biology describe increased sodium and water excretion through a combination of altered glomerular haemodynamics and reduced tubular sodium reabsorption, with cGMP as the mediator (PMID 31398927). Podocyte-level work on cGMP signalling has been used to study how the filtration barrier itself responds to these signals (PMID 12012390). The kidney is a crossroads for several peptide systems, a 2014 review of GLP-1 effects in the kidney described natriuretic and haemodynamic renal responses to a different gut-derived peptide, which is a useful reminder that sodium handling is governed by overlapping hormonal inputs rather than one pathway (PMID 24791975).

Vasculature: tone and permeability

Reviews of cardiovascular effects describe natriuretic peptide signalling as vasorelaxant, lowering vascular resistance through smooth-muscle cGMP, and as a contributor to fluid shift between the vascular and interstitial compartments (PMID 16492551). The 2019 pleiotropy review grouped these vascular actions with effects on endothelial function and cardiac remodelling under a single cGMP-driven framework (PMID 31398927).

Counter-regulation of the renin-angiotensin-aldosterone system

A consistent theme in the reviews is that natriuretic peptides act in opposition to vasoconstrictor and sodium-retaining systems. The 2020 endocrine review described the natriuretic peptide axis as a counter-regulatory arm to the renin-angiotensin-aldosterone system and sympathetic drive, relevant to blood pressure and cardiometabolic phenotypes (PMID 32537542). A 2025 review of antihypertensive pharmacotherapeutics discussed drug strategies that engage the natriuretic peptide system among newer approaches to blood-pressure control (PMID 40265521).

How the signal is switched off: clearance and degradation

Two routes are described. The first is receptor-mediated: NPR-C binds circulating peptide and internalises it, acting as a sink that sets the ambient concentration reaching NPR-A, as summarised in reviews of natriuretic peptide signalling (PMID 31398927). Internalisation itself is studied with established cell-biology techniques; a 2021 methods chapter described approaches for monitoring endocytosis in astrocytes, illustrating the kind of assay used to track receptor trafficking in intact cells (PMID 33222129).

The second is enzymatic degradation by peptidases, which is the pharmacological rationale behind drug classes that raise endogenous natriuretic peptide tone rather than supplying peptide. The 2025 antihypertensive review placed such strategies within the current and emerging blood-pressure drug landscape (PMID 40265521), and the 2020 endocrine review discussed how natriuretic peptide availability relates to cardiometabolic disease states (PMID 32537542).

Established mechanism versus proposed mechanism

Proposed mechanisms still under investigation

Pulmonary circulation and hypoxia

A 2018 review examined the regulation, signalling and functions of hormonal peptides in pulmonary vascular remodelling during hypoxia, placing natriuretic peptide signalling among the peptide systems implicated in how pulmonary vessels respond to low oxygen (PMID 29383676). Work of this type is predominantly experimental and does not establish clinical effect.

Prohormone fragments

The 2021 review of ANP(31-67) argued that this mid-region fragment has signalling properties of its own and described it as a candidate factor in cardiovascular disease research (PMID 34305645). Readers should note the distinction: evidence about a fragment is not automatically evidence about the full-length peptide.

Cardiometabolic signalling

The 2020 endocrine review discussed natriuretic peptides in relation to obesity, insulin resistance and related cardiometabolic phenotypes, framing low natriuretic peptide tone as a feature observed in some of these states (PMID 32537542). The 2019 pleiotropy review likewise extended the peptide family's described actions beyond blood pressure alone (PMID 31398927).

Adverse Effects and Tolerability: What Studies Report

The sources summarised here are mechanism and pharmacology reviews rather than safety databases, so they do not provide adverse-event tables. What they do report is the pharmacological direction of effect: the 2005 cardiovascular pharmacology review described natriuretic peptide signalling as lowering vascular resistance and promoting fluid loss (PMID 16492551), and the 2019 review described the same cGMP-driven haemodynamic and renal actions across tissues (PMID 31398927). Any agent engaging this axis therefore interacts directly with blood pressure and volume status, which is why the 2025 antihypertensive review discussed such strategies in a prescribing context (PMID 40265521). No dosing information is provided on this page, and none of the cited reviews supports self-directed use.

What the mechanism literature does not settle

1. Receptor pharmacology is not outcome data. Reviews describe NPR-A signalling clearly (PMID 31398927) without establishing clinical benefit for any particular use.
2. Cell and animal findings carry labels for a reason. Podocyte cGMP work (PMID 12012390) and hypoxic pulmonary remodelling research (PMID 29383676) describe mechanism, not human endpoints.
3. Fragment versus full peptide. The ANP(31-67) literature is reviewed separately for good reason (PMID 34305645).
4. Short plasma persistence. Clearance-receptor and enzymatic degradation pathways are a central design problem discussed in the drug-development literature (PMID 40265521).

Related reading

For background on what the peptide is, how it is measured and how the literature is organised, see the overview page: Atrial Natriuretic Peptide.

References

• Cardiovascular Pleiotropic Effects of Natriuretic Peptides (International Journal of Molecular Sciences, 2019)
• The Importance of Natriuretic Peptides in Cardiometabolic Diseases (Journal of the Endocrine Society, 2020)
• Cardiovascular effects (Advances in Pharmacology, 2005)
• Cyclic GMP signaling in podocytes (Microscopy Research and Technique, 2002)
• Atrial Natriuretic Peptide(31-67): A Novel Therapeutic Factor for Cardiovascular Diseases (Frontiers in Physiology, 2021)
• Regulation, signalling and functions of hormonal peptides in pulmonary vascular remodelling during hypoxia (Endocrine, 2018)
• Novel approaches in antihypertensive pharmacotherapeutics (Current Opinion in Nephrology and Hypertension, 2025)
• The Role of Oxytocin in Cardiovascular Protection (Frontiers in Psychology, 2020)
• Effects of GLP-1 in the kidney (Reviews in Endocrine & Metabolic Disorders, 2014)
• Protein phosphatase 5 (The International Journal of Biochemistry & Cell Biology, 2008)
• Methods for Monitoring Endocytosis in Astrocytes (Methods in Molecular Biology, 2021)